Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSRN-1734 is a transient receptor potential vanilloid 4 (TRPV4) antagonist, blocking calcium influx induced by the TRPV4 agonist 4α-phorbol 12,13-didecanoate (Item No. 20446) with IC50 values of 2.3, 5.9, and 3.2 µM for human, mouse, and rat TRPV4, respectively.1 It is selective for TRPV4 over TRPV1, TRPV3, and TRPM8 (IC50s = >100, >30, and >30 µM, respectively). RN-1734 (10 µM) reduces GSK1016790A-induced increases in glycine-activated current (IGly) from 34.5 to 0.97% in mouse hippocampal neurons in vitro.2 It blocks arteriolar dilation induced by GSK1016790A (Item No. 17289) and increases myogenic tone in rat cremaster arterioles ex vivo when used at a concentration of 30 µM.3 RN-1734 (1 mg/kg, i.p.) reduces edema and MAPK signaling induced by traumatic brain injury in rats.4 It also inhibits breakdown of the blood-retinal barrier in streptozotocin-induced diabetic rats when administered at a dose of 100 µM.5
WARNING This product is not for human or veterinary use.
1. Identification and characterization of novel TRPV4 modulators. Biochem. Biophys. Res. Commun. 389(3), 490-494 (2009).
2. Transient receptor potential vanilloid 4 activation-
3. Low intravascular pressure activates endothelial cell TRPV4 channels, local Ca2+ events, and IKCa channels, reducing arteriolar tone. Proc. Natl. Acad. Sci. USA 109(44), 18174-18179 (2012).
4. Transient receptor potential vanilloid type 4 channels mediate Na-
5. Dual contribution of TRPV4 antagonism in the regulatory effect of vasoinhibins on blood-